NCT03497195 (TB) is a NA clinical trial of Screening at community level in Tuberculosis, sponsored by University of Alabama at Birmingham.

Who is sponsoring NCT03497195?

NCT03497195 is sponsored by University of Alabama at Birmingham.

What drugs are being tested in NCT03497195?

Interventions in NCT03497195: Screening at community level.

What condition does NCT03497195 study?

NCT03497195 studies Tuberculosis.

Is NCT03497195 still recruiting?

NCT03497195 is currently completed. Last updated 25 September 2019.

Last reviewed 2019-09-25 · How we verify

NCT03497195: TB

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Achieving Tuberculosis (TB) Control In Zambia

Completed NA Last updated 25 September 2019

What this trial tests

NA trial testing Screening at community level in Tuberculosis in 18,194 participants. Completed in 31 December 2018.

Timeline

1 July 2017

Primary endpoint
31 December 2018

31 December 2018

Quick facts

Lead sponsor	University of Alabama at Birmingham
Phase	NA
Status	Completed
Study type	INTERVENTIONAL
Allocation	non randomized
Design	sequential
Masking	none
Primary purpose	diagnostic
Enrollment	18,194
Start date	1 July 2017
Primary completion	31 December 2018
Estimated completion	31 December 2018
Sites	1 location across Zambia

Drugs / interventions tested

Screening at community level

Conditions studied

Tuberculosis — all drugs for Tuberculosis →

Sponsor

University of Alabama at Birmingham

Who can join

18 and older, any sex, with Tuberculosis. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

To achieve TB control, innovative case finding interventions are needed that will reach the broader affected population including those that do not access the health facilities. Systematic community case finding with highly sensitive screening and diagnostic tools are needed. At the facility level, the index of suspicion for TB by health care workers needs to be raised to ensure that all those that need TB screening are appropriately screened.

Publications & conference data

2 peer-reviewed publications reference this trial (live from Europe PMC):

Xpert MTB/RIF and Xpert MTB/RIF Ultra for pulmonary tuberculosis and rifampicin resistance in adults.
Horne DJ, Kohli M, Zifodya JS, Schiller I, et al · · 2019 · cited 178× · PMID 31173647 · DOI 10.1002/14651858.cd009593.pub4
Xpert Ultra versus Xpert MTB/RIF for pulmonary tuberculosis and rifampicin resistance in adults with presumptive pulmonary tuberculosis.
Zifodya JS, Kreniske JS, Schiller I, Kohli M, et al · · 2021 · cited 136× · PMID 33616229 · DOI 10.1002/14651858.cd009593.pub5

Verify or expand the search:

Other recruiting trials for Tuberculosis

Currently open trials in the same condition.

NCT05917210 — Peer-led Implementation of TB-HIV Education and Adherence Counseling in Uganda · NA · recruiting
NCT07170735 — Quantitative Measurement of Plasma and Urine MTB Cell-free DNA Level · recruiting
NCT07484490 — Effects of the Active Cycle of Breathing Technique With and Without Balloon Blowing Therapy in Tuberculosis · NA · recruiting
NCT06318416 — Precision Rifampin Trial for Personalized Dosing · Phase 1 · recruiting
NCT07170800 — A Phase 2b Clinical Study of JDB0131 Benzenesulfonate Tablets · Phase 2 · recruiting

Other University of Alabama at Birmingham trials

Trials by the same sponsor.

NCT04922229 — Comparative Effectiveness in the Management of Irreversible Pulpitis · NA · not yet recruiting
NCT05060380 — Feasibility of a Novel Resistance Exercise in Individuals With Osteoporosis · NA · withdrawn
NCT04768777 — Behavioral Intervention for Physical Activity and Sexual Dysfunction in Multiple Sclerosis · NA · not yet recruiting
NCT06320951 — VITAL-IMPACT: Improving Cardiometabolic Health in Black Individuals Through Therapeutic Augmentation of Cyclic Guanosine · Phase 2 · not yet recruiting
NCT07564934 — Leveraging Extended Reality Exergaming and Telehealth to Improve Physical Activity and Health in Children With Disabilit · Phase 2 · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03497195 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by University of Alabama at Birmingham
Last refreshed: 25 September 2019

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03497195.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing